AUSDRISK — Australian Type 2 Diabetes Risk Tool
10-item validated risk assessment tool for identifying Australians at high risk of developing type 2 diabetes within 5 years. Also used internationally. Score ≥12 = high risk. Equivalent to FINDRISC adapted for Australian population.
Score interpretation
AUSDRISK <12 — low 5-year risk of type 2 diabetes
→ General healthy lifestyle advice; maintain healthy weight; physical activity ≥150 min/week; reassess every 3 years with risk tool
AUSDRISK 12–15 — intermediate 5-year risk (~1 in 14 chance)
→ Fasting glucose or HbA1c; review modifiable risk factors (weight, activity, diet); consider referral to diabetes prevention programme; annual reassessment
AUSDRISK ≥16 — high 5-year risk (~1 in 7 or higher)
→ Fasting plasma glucose and HbA1c; if pre-diabetic (FPG 5.6–6.9 or HbA1c 39–47 mmol/mol): intensive lifestyle programme; consider metformin in high-risk cases; 6-monthly review; address all cardiovascular risk factors
Interpretation bands for the AUSDRISK. Apply clinical judgement and local guidance.
References
- Chen L et al. AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures. Med J Aust. 2010;192(4):197–202.
Related
Curated clinical cross-links plus same-class fallbacks.
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Thiamine (IV/IM — Pabrinex) · Vitamin B1 (Thiamine) — deficiency treatment / Wernicke's encephalopathy prevention
- Botulinum Toxin Type A (ENT) · Neuromuscular Blocking Agent (Botulinum Toxin)
- Anthrax Vaccine · Vaccine (Bacterial — Anthrax Prevention)
- Edoxaban (AF Stroke Prevention / VTE) · Direct Factor Xa Inhibitor (DOAC)
- Valganciclovir · Prodrug Antiviral — CMV Prevention and Treatment (Oral)
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.